title: Treatment of Gram-positive left-sided infective endocarditis with daptomycin.
abstract: The aim of this study was to evaluate the effectiveness of daptomycin in left-sided infective endocarditis (IE) patients. Fourteen patients with left heart endocarditis, monitored with a diagnosis of IE based on modified Duke criteria between July 2010 and May 2011, and receiving daptomycin as monotherapy, were enrolled. The success of daptomycin in these patients was revealed with improvements in microbiological, biochemical, and radiologic findings, as well as physical examination findings. Patient average age was 63.5 ± 14.2 years (36-80 years); 8 (57 %) were men and 6 (43 %) women. The pathogens methicillin-resistant Staphylococcus aureus (71.5 %), Streptococcus mutans (21.5 %), and methicillin-sensitive Staphylococcus aureus (7 %) were isolated from our patients. Daptomycin was used in initial treatment in 5 (36 %) patients; treatment was subsequently modified to daptomycin in 9 (64 %) patients as a consequence of drug serum level insufficiency, agent sensitivity to the drug administered, or drug side effects. Thirteen patients were discharged in a healthy condition, with successful surgical treatment in 5 (36 %). Only 1, an 80-year-old IE patient, was lost from advanced cardiac failure. No significant side effects were seen in any patient receiving daptomycin. The most frequent side effects were minimal rises in serum CPK levels during treatment; these values returned to normal after treatment. Daptomycin can be used successfully in left heart endocarditis with no significant side effects. Studies involving a wider patient series are now needed to support the use of daptomycin in left heart endocarditis.
authors.affiliation: Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Karadeniz Technical University, 61080, Trabzon, Turkey. eselkaya@yahoo.com
authors.forename: Selçuk
authors.initials: S
authors.lastname: Kaya
authors.forename: Gürdal
authors.initials: G
authors.lastname: Yilmaz
authors.forename: Ahmet
authors.initials: A
authors.lastname: Kalkan
authors.forename: Barış
authors.initials: B
authors.lastname: Ertunç
authors.forename: Iftihar
authors.initials: I
authors.lastname: Köksal
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D017576:Daptomycin / Q000009:adverse effects / Q000627:therapeutic use*; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013290:Streptococcal Infections / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D017576:Daptomycin